Evidence map›Paper›PMID 41445644›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Divergent patterns of cognitive decline in preclinical Alzheimer's disease: implications for secondary prevention trials.

Runpeng Li, Oliver Langford, Philip S Insel, Reisa A Sperling, Rema Raman, Paul S Aisen, Michael C Donohue

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Funding

The Alzheimer's Clinical Trial Consortium - Down Syndrome Network (ACTC- DSN)U24AG057437 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Paul S. Aisen, RONALD C PETERSEN · 2018 to 2026
$198.4M
RECRUITMENT COREU19AG010483 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FELDMAN, HOWARD · 2013 to 2020
$80.6M
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Open-Label Extension StudyR01AG063689 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI AISEN, PAUL S., SPERLING, REISA A. · 2019 to 2024
$30.8M
NIA NIH HHS R01 AG063689NIA NIH HHS U19 AG010483NIA NIH HHS U24 AG057437
6 · The paper itself

Abstract

Background: Alzheimer's disease biomarkers in cognitively unimpaired older adults are associated with later cognitive and clinical decline, yet substantial heterogeneity in the timing and rate of decline remains insufficiently characterized. This study aims to identify subgroups of cognitive decline among biomarker-defined cognitively unimpaired adults and determine baseline predictors of heterogeneity in preclinical Alzheimer's disease progression. Methods: Longitudinal data was analyzed from the Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) Study, which enrolled amyloid-positive participants, and the parallel LEARN Study, which enrolled amyloid-negative individuals meeting all other A4 criteria. Participants completed baseline amyloid PET, plasma P-tau217, structural MRI, and serial cognitive assessments. Latent Class Mixed-Effects Models (LCMMs) were used to identify distinct cognitive trajectory classes. Associations between class membership and demographic, clinical, and biomarker characteristics were evaluated. The primary outcome was longitudinal change in the Preclinical Alzheimer Cognitive Composite (PACC). Findings: Three cognitive trajectory classes were identified: stable, slow decliners, and fast decliners. Higher plasma P-tau217, smaller hippocampal volume, and elevated tau PET were associated with greater odds of belonging to declining classes. Among amyloid-positive individuals, approximately 70% were classified as stable over the observed follow-up interval. These stable individuals likely contribute little to the power of preclincal Alzheimer's trials. Interpretation: Latent class modeling reveals marked heterogeneity in preclinical cognitive trajectories, even among individuals with biomarker evidence of Alzheimer pathology. The high proportion of stable individuals, though consistent with the long presymptomatic interval, has important implications for prevention trial design, particularly regarding inclusion criteria, outcome measures, and treatment effect assumptions. Identifying subgroups of decline may improve prognostic modeling and guide enrichment strategies for precision secondary prevention trials. Funding: US National Institutes of Health, Eli Lilly, Alzheimer's Association, Foundation for the National Institutes of Health, GHR Foundation, Davis Alzheimer Prevention Program, Yugilbar Foundation, Avid Radiopharmaceuticals, Cogstate, Albert Einstein College of Medicine, Foundation for Neurologic Diseases, and Epstein Family Foundation.

Identifiers

PMID41445644
PMCPMC12723760

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.